The Genomic Landscape of Leukemic Transformation of Myeloproliferative Neoplasm

The BCR/ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocytosis, polycythemia vera, and myelofibrosis. Leukemic transformation (LT) of MPNs carries a particularly dismal prognosis, with a median survival of less than 6 months. Despite outcomes that are much worse than many other subtypes of acute myeloid leukemia (AML), most patients with LT are treated with standard induction chemotherapy with minimal benefit. Given the marked disparities in outcomes with induction chemotherapy between de novo AML and LT, it is critical to understand the biologic and genomic factors which differentiate LT from de novo AML on a molecular level.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research